|Bid||110.38 x 900|
|Ask||111.21 x 1000|
|Day's Range||111.01 - 112.98|
|52 Week Range||81.66 - 114.46|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||31.56|
|Forward Dividend & Yield||2.16 (1.91%)|
|1y Target Est||N/A|
Senseonics Holdings Inc. has slapped a new label on its blood-sugar monitoring system, a move that boils down to one thing for diabetes patients: fewer finger sticks. The Germantown company — whose implantable continuous glucose monitoring (CGM) system senses a person’s glucose levels to determine if he or she needs insulin, food or exercise — is starting to market the product as an alternative to the decades-old step of pricking a finger multiple times a day to elicit a drop of blood. Senseonics (NYSE: SENS) earned that right to market its Eversense CGM system as a replacement for finger sticks to measure glucose, per approval by the Food and Drug Administration this past summer.
Zacks.com featured highlights include: Target, Medtronic Public, Arconic, Science Applications International and Bristol-Myers Squibb
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) ("Elekta") to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement.
Investors need to be bold enough to bet on trend-shifting consumption habits emanating from Industry 4.0, which will stand them in good stead.
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
At Insider Monkey, we pore over the filings of around 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this article, […]
Last week saw the newest quarterly earnings release from Medtronic plc (NYSE:MDT), an important milestone in the...
Medtronic stock briefly edged into a buy zone in Tuesday trades after the medical technology company topped Wall Street's quarterly expectations and raised its full-year earnings outlook.
U.S. stocks slipped back from record highs on Wednesday on disappointing earnings results and doubts about a U.S. - China trade deal
Zacks.com featured highlights include: Medtronic Public, Arconic, Nasdaq, Hewlett Packard and Target
Medtronic (MDT) delivered earnings and revenue surprises of 2.34% and 0.38%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Medtronic PLC surged 2.4% in premarket trading Tuesday, after the medical technology company reported fiscal second-quarter earnings that rose above expectations, and raised its full-year profit outlook, but the stock slipped 1.1% in premarket trading to extend a pullback from the previous session's all-time intraday high. Net income for the quarter to Oct. 25 rose to $1.36 billion, or $1.01 a share, from $1.12 billion, or 82 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share came to $1.31, above the FactSet consensus of $1.28. Revenue rose 3.0% to $7.71 billion, above the FactSet consensus of $7.66 billion, as beats in diabetes, restorative therapies and minimally invasive therapies segment revenue offset a slight miss in cardiac and vascular revenue. For fiscal 2020, the company affirmed its revenue growth outlook of 4.0% but raised its adjusted EPS guidance range to $5.57 to $5.63 from $5.54 to $5.60. The stock had closed at a record $112.06 on Friday, then rose to an record intraday high of $114.46 on Monday before reversing to closed down 0.7%. The stock has rallied 22.3% year to date through Monday, while the S&P 500 has climbed 24.5%.
Medtronic dipped to $111.08 Tuesday after the medical equipment maker beat Wall Street's second-quarter earnings expectations, but its cardiac and vascular unit missed revenue forecasts.